You're one step closer to unlocking our suite of comprehensive and robust tools.
Fill out the form so we can connect you to the right person.
If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.
BARD1 Life Sciences plans to raise A$1.3M via placement of shares
Gauging Supply Chain Risk In Volatile Times
Cannabis: Hashing Out a Budding Industry
IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help
The Market Intelligence Platform
BARD1 Life Sciences Ltd. agreed to sell 86,666,666 shares at 1.5 Australian cents each to a group of investors.
The company expects to raise A$1.3 million through the placement, which will go toward its ongoing research and development programs, as well as commercial initiatives and general working capital purposes.
The placement is expected to settle by March 26.
Australia-based BARD1 Life Sciences develops therapies and diagnostic tests for cancer.